JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• A Multiple-dose Study of LY3031207 in Healthy Participants

  NCT01632566

  Condition:   Healthy Volunteers
  Interventions:   Drug: Placebo;   Drug: LY3031207;   Drug: Celecoxib;   Drug: Simvastatin
  Sponsor:   Eli Lilly and Company
  Terminated
• Exercise Programming in Breast Cancer Patients

  NCT04013568

  Condition:   Breast Cancer
  Intervention:   Other: Exercise
  Sponsor:   University of Hawaii
  Not yet recruiting
• Survivorship and Patient Outcomes of Primary Total Hip Arthroplasty With the Ovation Hip System

  NCT03986918

  Conditions:   Joint Diseases;   Osteoarthritis, Hip;   Rheumatoid Arthritis;   Psoriatic Arthritis;   Avascular Necrosis of Hip
  Intervention:   Device: Routine Total Hip Arthroplasty
  Sponsor:   Ortho Development Corporation
  Recruiting
• Online and Mobile Mindfulness Intervention to Improve the Well-Being of Cancer Survivors

  NCT03581357

  Condition:   Cancer
  Intervention:   Behavioral: Online Mindful Meditation
  Sponsors:   University of Hawaii;   VA Palo Alto Health Care System
  Recruiting
• Hula, a Physical Activity Intervention for Female-Cancer Survivors

  NCT02351479

  Conditions:   Physical Activity;   Breast Cancer;   Cervical Cancer;   Ovarian Cancer;   Endometrial Cancer
  Intervention:   Behavioral: Hula
  Sponsor:   University of Hawaii
  Completed
• Reducing Head Impact Exposure in Hawaii High School Football

  NCT04020874

  Conditions:   Head Trauma;   Cognitive Change;   Confidence, Self;   Sports Injuries in Children
  Interventions:   Behavioral: HuTT-2x;   Behavioral: HuTT-4x
  Sponsors:   University of Massachusetts, Lowell;   Gary O. Galiher Foundation;   University of Hawaii;   University of Michigan;   Children's National Health System
  Recruiting
• Hawaii Patient Reward And Incentives to Support Empowerment

  NCT02123251

  Condition:   Diabetes Mellitus
  Intervention:   Behavioral: Financial Incentives
  Sponsors:   University of Hawaii;   Centers for Medicare and Medicaid Services;   Hawaii Department of Human Services (DHS);   Kaiser Permanente;   RTI International;   IMPAQ International, LLC.;   Econometrica, Inc.
  Completed
• A Study of LY2495655 in Healthy Subjects

  NCT01341470

  Condition:   Healthy Volunteer
  Interventions:   Drug: LY2495655;   Drug: Placebo
  Sponsor:   Eli Lilly and Company
  Completed
• Comparative User Experiences With BD Nano™ PRO 4mm x 32G Extra Thin Wall Pen Needle vs Three Commercially Available Pen Needles

  NCT03878758

  Condition:   Diabetes
  Interventions:   Device: BD Nano™ PRO;   Device: 33G Artsana Insupen Extr3me;   Device: 34G Artsana Insupen Extr3me;   Device: Simple Diagnostics Comfort EZ™
  Sponsor:   Becton, Dickinson and Company
  Completed
• Episcleral Brachytherapy for the Treatment of Wet AMD

  NCT02988895

  Condition:   Macular Degeneration, Choroidal Neovascularization
  Intervention:   Radiation: episcleral brachytherapy
  Sponsor:   Salutaris Medical Devices, Inc.
  Recruiting
• Pushing Behaviors in Individuals Post-stroke

  NCT02190734

  Condition:   Stroke
  Interventions:   Other: Sitting in wheel chair;   Other: Gait training on treadmill;   Other: Gait training overground
  Sponsor:   Shirley Ryan AbilityLab
  Completed
• The Gore SCAFFOLD Clinical Study

  NCT01901874

  Conditions:   Carotid Artery Disease;   Carotid Artery Stenosis
  Intervention:   Device: Carotid Artery Stenting
  Sponsor:   W.L.Gore & Associates
  Active, not recruiting
• A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol

  NCT01618916

  Condition:   Healthy Volunteers
  Interventions:   Drug: LY3015014;   Other: Placebo
  Sponsor:   Eli Lilly and Company
  Completed
• NEW Keiki Family Based Intervention to Combat Childhood Obesity

  NCT02691039

  Conditions:   Obesity;   Overweight
  Intervention:  
  Sponsor:   Malia Shimokawa, MD
  Completed
• Clinical Evaluation of Acuity 200 (Fluoroxyfocon A) RGP Contact Lens

  NCT03971227

  Condition:   Refractive Errors
  Interventions:   Device: Acuity 200 (Fluoroxyfocon A) contact lens;   Device: Acuity 100 (Hexafocon A) contact lens
  Sponsors:   Acuity Polymers, Inc.;   Andre Vision and Device Research
  Enrolling by invitation
• A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease

  NCT02713256

  Condition:   Graves' Disease
  Intervention:   Drug: CFZ533
  Sponsor:   Novartis Pharmaceuticals
  Completed
• A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease

  NCT03117738

  Condition:   Alzheimer Disease
  Interventions:   Drug: AstroStem;   Other: Placebo-Control
  Sponsor:   Nature Cell Co. Ltd.
  Active, not recruiting
• Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age

  NCT03642847

  Condition:   Pneumococcal Infections
  Interventions:   Biological: Prevnar 13;   Biological: multivalent pneumococcal conjugate formulation 1;   Biological: multivalent pneumococcal conjugate formulation 2
  Sponsor:   Pfizer
  Completed
• Evaluating the User Performance and Experience of Nucleus Pen vs. Commercially Available Pen Needle

  NCT03267264

  Condition:   Diabetes
  Interventions:   Device: BD Nano™ vs Nucleus;   Device: NovoFine® vs Nucleus;   Device: NovoTwist®/NovoFine® Plus vs Nucleus;   Device: Other Commercially Available Pen Needles (Unifine® Pentips®/Mylife Clickfine®) vs Nucleus
  Sponsor:   Becton, Dickinson and Company
  Completed
• Work Ability in Young Adult Cancer Survivors

  NCT03148080

  Condition:   Cancer Survivor
  Interventions:   Procedure: Cognitive Assessment;   Other: Questionnaire Administration
  Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
  Recruiting
• S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

  NCT00822120

  Conditions:   Lymphoma;   Nonneoplastic Condition
  Interventions:   Biological: bleomycin sulfate;   Biological: filgrastim;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine sulfate;   Drug: vincristine sulfate
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer

  NCT02308085

  Condition:   Early Breast Cancer
  Intervention:   Other: Endocrine therapy interruption
  Sponsors:   International Breast Cancer Study Group;   Alliance for Clinical Trials in Oncology;   Canadian Cancer Trials Group;   Breast International Group
  Recruiting
• Clinical Study Evaluating the Performance of HEMOBLAST Bellows Compared to FLOSEAL Hemostatic Matrix in Cardiothoracic Operations

  NCT03725098

  Condition:   Cardiothoracic Surgery
  Interventions:   Device: HEMOBLAST Bellows;   Device: FLOSEAL
  Sponsor:   Biom'Up SA
  Completed
• Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

  NCT00651261

  Condition:   Leukemia
  Interventions:   Drug: cytarabine;   Drug: daunorubicin;   Drug: midostaurin;   Other: placebo;   Drug: dexamethasone acetate
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Novartis Pharmaceuticals
  Active, not recruiting
• Tenofovir Alafenamide in Preventing Liver Complications in Participants With Current or Past Hepatitis B Virus Who Are Receiving Anti-Cancer Therapy for Solid Tumors

  NCT03887702

  Conditions:   Hepatitis B Virus Positive;   Malignant Solid Neoplasm
  Interventions:   Other: Best Practice;   Other: Laboratory Biomarker Analysis;   Drug: Tenofovir Alafenamide
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

  NCT03851445

  Condition:   Previously Treated Non-Small Cell Lung Cancer
  Intervention:   Drug: Screening Platform
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

  NCT03793179

  Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   PD-L1 Positive;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8
  Interventions:   Drug: Carboplatin;   Biological: Pembrolizumab;   Drug: Pemetrexed
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

  NCT03768414

  Conditions:   Stage III Distal Bile Duct Cancer AJCC v8;   Stage III Gallbladder Cancer AJCC v8;   Stage III Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIA Distal Bile Duct Cancer AJCC v8;   Stage IIIA Gallbladder Cancer AJCC v8;   Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIB Distal Bile Duct Cancer AJCC v8;   Stage IIIB Gallbladder Cancer AJCC v8;   Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IV Distal Bile Duct Cancer AJCC v8;   Stage IV Gallbladder Cancer AJCC v8;   Stage IV Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IVA Gallbladder Cancer AJCC v8;   Stage IVB Gallbladder Cancer AJCC v8;   Unresectable Extrahepatic Bile Duct Carcinoma;   Unresectable Gallbladder Carcinoma;   Unresectable Intrahepatic Cholangiocarcinoma
  Interventions:   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Drug: Nab-paclitaxel
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Increasing Patients' Engagement in Breast Cancer Surgery Decision-Making

  NCT03766009

  Conditions:   Breast Cancer Stage 0;   Breast Cancer Stage I;   Breast Cancer Stage II;   Breast Cancer Stage III
  Interventions:   Other: Usual Care;   Other: Web-based decision aid
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Agency for Healthcare Research and Quality (AHRQ)
  Recruiting
• Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

  NCT03723928

  Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Prognostic Stage IV Breast Cancer AJCC v8;   Elevated CA15-3 or CEA or CA27-29
  Interventions:   Other: Usual care disease monitoring;   Other: Serum Tumor Marker directed disease monitoring;   Other: Quality-of-Life Assessment;   Other: Anxiety Questionnaire Administration
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia

  NCT03701282

  Conditions:   CCND1/IGHG1 Fusion Negative;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   t(11;14) Negative
  Interventions:   Drug: Ibrutinib;   Biological: Obinutuzumab;   Other: Quality-of-Life Assessment;   Drug: Venetoclax
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery

  NCT03698019

  Conditions:   Acral Lentiginous Melanoma;   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Mucosal Melanoma;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8
  Interventions:   Biological: Pembrolizumab;   Procedure: Therapeutic Conventional Surgery
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Olaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer

  NCT03660826

  Conditions:   Endometrial Undifferentiated Carcinoma;   Endometrioid Adenocarcinoma;   Recurrent Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage IV Uterine Corpus Cancer AJCC v7;   Stage IVA Uterine Corpus Cancer AJCC v7;   Stage IVB Uterine Corpus Cancer AJCC v7
  Interventions:   Drug: Cediranib;   Drug: Cediranib Maleate;   Drug: Olaparib
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia

  NCT03654768

  Condition:   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  Interventions:   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Nilotinib;   Drug: Ruxolitinib Phosphate
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Pembrolizumab and Epacadostat in Treating Patients With Recurrent, Persistent, or Progressive Ovarian Clear Cell Carcinoma

  NCT03602586

  Conditions:   Malignant Ovarian Clear Cell Tumor;   Recurrent Ovarian Carcinoma
  Interventions:   Drug: Epacadostat;   Biological: Pembrolizumab
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Suspended
• Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

  NCT03578081

  Condition:   Malignant Neoplasm
  Interventions:   Drug: Palonosetron Hydrochloride;   Drug: Ondansetron Hydrochloride;   Drug: Dexamethasone;   Drug: Fosaprepitant Dimeglumine;   Drug: Olanzapine;   Other: Placebo
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer

  NCT03418961

  Conditions:   Cardiotoxicity;   HER2/Neu Positive;   Metastatic Malignant Neoplasm in the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Drug: Carvedilol;   Other: Laboratory Biomarker Analysis;   Other: Patient Observation
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

  NCT03365882

  Conditions:   Colon Adenocarcinoma;   ERBB2 Gene Amplification;   Rectal Adenocarcinoma;   Recurrent Colon Carcinoma;   Recurrent Rectal Carcinoma;   Stage III Colon Cancer AJCC v7;   Stage III Rectal Cancer AJCC v7;   Stage IIIA Colon Cancer AJCC v7;   Stage IIIA Rectal Cancer AJCC v7;   Stage IIIB Colon Cancer AJCC v7;   Stage IIIB Rectal Cancer AJCC v7;   Stage IIIC Colon Cancer AJCC v7;   Stage IIIC Rectal Cancer AJCC v7;   Stage IV Colon Cancer AJCC v7;   Stage IV Rectal Cancer AJCC v7;   Stage IVA Colon Cancer AJCC v7;   Stage IVA Rectal Cancer AJCC v7;   Stage IVB Colon Cancer AJCC v7;   Stage IVB Rectal Cancer AJCC v7
  Interventions:   Biological: Cetuximab;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Biological: Pertuzumab;   Biological: Trastuzumab;   Device: HER-2 testing
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

  NCT03244384

  Conditions:   Stage II Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
  Interventions:   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Non-metastatic Colorectal Cancer Receiving Chemotherapy

  NCT03186638

  Conditions:   Caregiver;   Cognitive Impairment;   Stage 0 Colorectal Cancer AJCC v6 and v7;   Stage I Colorectal Cancer AJCC v6 and v7;   Stage II Colorectal Cancer AJCC v7;   Stage IIA Colorectal Cancer AJCC v7;   Stage IIB Colorectal Cancer AJCC v7;   Stage IIC Colorectal Cancer AJCC v7;   Stage III Colorectal Cancer AJCC v7;   Stage IIIA Colorectal Cancer AJCC v7;   Stage IIIB Colorectal Cancer AJCC v7;   Stage IIIC Colorectal Cancer AJCC v7
  Interventions:   Drug: Ibuprofen;   Other: Placebo;   Other: Questionnaire Administration
  Sponsors:   Gary Morrow;   National Cancer Institute (NCI)
  Recruiting
• Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

  NCT03180294

  Conditions:   Breast Carcinoma;   Cervical Carcinoma;   Ovarian Carcinoma;   Postmenopausal;   Uterine Corpus Cancer;   Vaginal Carcinoma;   Vulvar Carcinoma
  Interventions:   Drug: Bupropion Hydrochloride;   Other: Placebo
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

  NCT03087708

  Conditions:   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
  Interventions:   Drug: Naloxegol;   Other: Placebo;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery

  NCT03033576

  Conditions:   Advanced Melanoma;   Melanoma of Unknown Primary;   Mucosal Melanoma;   Refractory Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma;   Unresectable Melanoma
  Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

  NCT02927249

  Condition:   Node Positive HER2 Negative Breast Cancer
  Interventions:   Other: Placebo;   Drug: Aspirin
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
  Recruiting
• Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

  NCT02921256

  Conditions:   Rectal Adenocarcinoma;   Stage II Rectal Cancer AJCC v7;   Stage III Rectal Cancer AJCC v7
  Interventions:   Drug: Capecitabine;   Drug: Fluorouracil;   Radiation: Intensity-Modulated Radiation Therapy;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Biological: Pembrolizumab;   Drug: Veliparib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

  NCT02912559

  Conditions:   Colon Adenocarcinoma;   DNA Repair Disorder;   Lynch Syndrome;   Stage III Colon Cancer AJCC v7;   Stage IIIA Colon Cancer AJCC v7;   Stage IIIB Colon Cancer AJCC v7;   Stage IIIC Colon Cancer AJCC v7
  Interventions:   Drug: Atezolizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

  NCT02893930

  Conditions:   Pancreatic Neuroendocrine Tumor G1;   Pancreatic Neuroendocrine Tumor G2;   Refractory Pancreatic Neuroendocrine Carcinoma
  Intervention:   Drug: Sapanisertib
  Sponsor:   National Cancer Institute (NCI)
  Suspended
• FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

  NCT02890355

  Conditions:   Metastatic Pancreatic Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage IV Pancreatic Cancer AJCC v6 and v7
  Interventions:   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Veliparib
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT02839707

  Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Undifferentiated Carcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Undifferentiated Carcinoma;   Platinum-Resistant Ovarian Carcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
  Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Quality-of-Life Assessment
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Suspended
• Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

  NCT02834013

  Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Angiosarcoma;   Apocrine Neoplasm;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Basal Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cervical Clear Cell Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Extramammary Paget Disease;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gallbladder Carcinoma;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Gestational Trophoblastic Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   PEComa;   Peritoneal Mesothelioma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Solid Neoplasm;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Somatic-Type Malignancy;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
  Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

  NCT02844816

  Conditions:   Recurrent Bladder Urothelial Carcinoma;   Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage I Bladder Urothelial Carcinoma AJCC v6 and v7
  Intervention:   Drug: Atezolizumab
  Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Active, not recruiting
• Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil

  NCT02822573

  Conditions:   Cognitive Dysfunction;   Memory Impairment
  Interventions:   Drug: Donepezil 5 mg;   Drug: Placebo
  Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
  Recruiting
• Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

  NCT02785913

  Conditions:   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Taselisib
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Cabozantinib S-Malate, Crizotinib, Savolitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

  NCT02761057

  Conditions:   Stage III Renal Cell Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma;   Unresectable Renal Cell Carcinoma
  Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Drug: Crizotinib;   Drug: Savolitinib;   Drug: Sunitinib;   Drug: Sunitinib Malate
  Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826

  Condition:   Breast Carcinoma
  Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
  Recruiting
• The National Myelodysplastic Syndromes (MDS) Study

  NCT02775383

  Condition:   Myelodysplastic Syndromes (MDS)
  Intervention:   Other: Therapeutic
  Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI)
  Recruiting
• Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

  NCT02601209

  Conditions:   High Grade Sarcoma;   Metastatic Leiomyosarcoma;   Metastatic Malignant Peripheral Nerve Sheath Tumor;   Metastatic Synovial Sarcoma;   Metastatic Undifferentiated Pleomorphic Sarcoma;   Metastatic Unresectable Sarcoma;   Myxofibrosarcoma;   Recurrent Leiomyosarcoma;   Recurrent Malignant Peripheral Nerve Sheath Tumor;   Recurrent Synovial Sarcoma;   Recurrent Undifferentiated Pleomorphic Sarcoma;   Stage III Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IV Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8;   Unresectable Leiomyosarcoma
  Interventions:   Drug: Pazopanib;   Drug: Pazopanib Hydrochloride;   Drug: Sapanisertib
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

  NCT02595944

  Conditions:   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  Intervention:   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

  NCT02562716

  Conditions:   Pancreatic Adenocarcinoma;   Resectable Pancreatic Carcinoma
  Interventions:   Drug: Fluorouracil;   Drug: Gemcitabine Hydrochloride;   Drug: Irinotecan Hydrochloride;   Drug: Oxaliplatin;   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;   Procedure: Pancreatectomy
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery

  NCT02500797

  Conditions:   Dedifferentiated Liposarcoma;   Gastrointestinal Stromal Tumor;   Locally Advanced Bone Sarcoma;   Locally Advanced Soft Tissue Sarcoma;   Metastatic Bone Sarcoma;   Metastatic Liposarcoma;   Metastatic Soft Tissue Sarcoma;   Metastatic Undifferentiated Pleomorphic Sarcoma;   Metastatic Unresectable Sarcoma;   Pleomorphic Liposarcoma;   Stage III Bone Sarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Bone Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Bone Sarcoma AJCC v7;   Stage IVB Bone Sarcoma AJCC v7;   Unresectable Bone Sarcoma;   Unresectable Liposarcoma;   Unresectable Soft Tissue Sarcoma
  Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Quality-of-Life Assessment
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967

  Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

  NCT02506153

  Conditions:   Metastatic Cutaneous Melanoma;   Metastatic Non-Cutaneous Melanoma;   Non-Cutaneous Melanoma;   Recurrent Cutaneous Melanoma;   Recurrent Non-Cutaneous Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage III Mucosal Melanoma of the Head and Neck AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Stage IVA Mucosal Melanoma of the Head and Neck AJCC v7;   Stage IVB Mucosal Melanoma of the Head and Neck AJCC v7;   Stage IVC Mucosal Melanoma of the Head and Neck AJCC v7
  Interventions:   Biological: Ipilimumab;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Biological: Recombinant Interferon Alfa-2b
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer

  NCT02466971

  Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Stage IB2 Cervical Cancer AJCC v6 and v7;   Stage II Cervical Cancer AJCC v7;   Stage II Vaginal Cancer AJCC v6 and v7;   Stage IIA Cervical Cancer AJCC v7;   Stage IIB Cervical Cancer AJCC v6 and v7;   Stage III Vaginal Cancer AJCC v6 and v7;   Stage IIIB Cervical Cancer AJCC v6 and v7;   Stage IVA Cervical Cancer AJCC v6 and v7;   Stage IVA Vaginal Cancer AJCC v6 and v7;   Vaginal Adenocarcinoma;   Vaginal Adenosquamous Carcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
  Interventions:   Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Internal Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Radiation: Radiation Therapy;   Drug: Triapine
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

  NCT02465060

  Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
  Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

  NCT02744092

  Conditions:   Cancer;   Venous Thromboembolism;   Deep Vein Thrombosis (DVT);   Pulmonary Embolism (PE);   Blood Clot
  Interventions:   Drug: Rivaroxaban;   Drug: Apixaban;   Drug: Edoxaban;   Drug: Dabigatran;   Drug: Warfarin;   Drug: Dalteparin;   Drug: Enoxaparin;   Drug: Fondaparinux
  Sponsors:   Alliance Foundation Trials, LLC.;   Patient-Centered Outcomes Research Institute
  Recruiting
• Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT02315430

  Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
  Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis
  Sponsor:   National Cancer Institute (NCI)
  Completed
• Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

  NCT02311933

  Conditions:   Estrogen Receptor Positive;   HER2/Neu Negative;   Recurrent Breast Carcinoma;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Tamoxifen Citrate;   Drug: Z-Endoxifen Hydrochloride
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery

  NCT02249949

  Condition:   Liposarcoma
  Intervention:   Drug: efatutazone
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Daiichi Sankyo, Inc.
  Active, not recruiting
• Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

  NCT02224781

  Conditions:   BRAF NP_004324.2:p.V600X;   Metastatic Melanoma;   Progressive Disease;   Recurrent Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma
  Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

  NCT02201992

  Conditions:   ALK Gene Rearrangement;   ALK Gene Translocation;   ALK Positive;   Stage IB Non-Small Cell Lung Carcinoma AJCC v7;   Stage II Non-Small Cell Lung Cancer AJCC v7;   Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Laboratory Biomarker Analysis
  Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
  Recruiting
• Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

  NCT02196181

  Conditions:   BRAF V600E Mutation Present;   BRAF V600K Mutation Present;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Melanoma
  Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738

  Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

  NCT02193282

  Conditions:   ALK Gene Rearrangement;   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

  NCT02339571

  Conditions:   Progressive Disease;   Recurrent Cutaneous Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma
  Interventions:   Biological: Ipilimumab;   Biological: Nivolumab;   Biological: Sargramostim
  Sponsor:   National Cancer Institute (NCI)
  Suspended
• S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer

  NCT02177695

  Condition:   Bladder Cancer
  Interventions:   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Methotrexate;   Drug: Vinblastine;   Drug: Doxorubicin;   Drug: Filgrastim
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer

  NCT02164916

  Condition:   Colorectal Cancer
  Interventions:   Biological: cetuximab;   Drug: irinotecan hydrochloride;   Drug: vemurafenib
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Roche-Genentech
  Active, not recruiting
• Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer

  NCT02152137

  Conditions:   Anaplastic Thyroid Cancer;   Recurrent Thyroid Cancer
  Interventions:   Drug: efatutazone;   Drug: paclitaxel
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Daiichi Sankyo, Inc.
  Active, not recruiting
• Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

  NCT02115282

  Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Positive;   HER2/Neu Negative;   Locally Advanced Breast Carcinoma;   Metastatic Breast Carcinoma;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Drug: Entinostat;   Drug: Exemestane;   Drug: Goserelin;   Drug: Goserelin Acetate;   Other: Placebo;   Other: Quality-of-Life Assessment
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer

  NCT02065687

  Conditions:   Endometrial Adenocarcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Endometrial Undifferentiated Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage III Uterine Corpus Cancer AJCC v7;   Stage IIIA Uterine Corpus Cancer AJCC v7;   Stage IIIB Uterine Corpus Cancer AJCC v7;   Stage IIIC Uterine Corpus Cancer AJCC v7;   Stage IV Uterine Corpus Cancer AJCC v7;   Stage IVA Uterine Corpus Cancer AJCC v7;   Stage IVB Uterine Corpus Cancer AJCC v7
  Interventions:   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Metformin Hydrochloride;   Drug: Paclitaxel;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer

  NCT02059265

  Conditions:   Endometrial Clear Cell Adenocarcinoma;   Estrogen Receptor Negative;   Ovarian Clear Cell Cystadenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Recurrent Uterine Corpus Carcinoma
  Interventions:   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

  NCT02003209

  Conditions:   Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Positive;   Stage IB Breast Cancer AJCC v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7
  Interventions:   Drug: Aromatase Inhibition Therapy;   Drug: Carboplatin;   Other: Cytology Specimen Collection Procedure;   Drug: Docetaxel;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Biological: Pertuzumab;   Other: Quality-of-Life Assessment;   Procedure: Therapeutic Conventional Surgery;   Biological: Trastuzumab;   Radiation: Whole Breast Irradiation
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

  NCT03055013

  Conditions:   Metastatic Malignant Neoplasm in Lymph Node;   Metastatic Malignant Neoplasm in the Adrenal Gland;   Metastatic Malignant Neoplasm in the Lung;   Metastatic Malignant Neoplasm in the Pancreas;   Metastatic Malignant Neoplasm in the Skin;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Renal Cell Carcinoma;   Oligometastasis;   Sarcomatoid Renal Cell Carcinoma;   Stage II Renal Cell Cancer AJCC v7;   Stage III Renal Cell Cancer AJCC v7;   Unclassified Renal Cell Carcinoma
  Interventions:   Procedure: Conventional Surgery;   Biological: Nivolumab;   Other: Patient Observation;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

  NCT01950390

  Conditions:   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Melanoma
  Interventions:   Biological: Bevacizumab;   Biological: Ipilimumab
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

  NCT01949337

  Conditions:   Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
  Interventions:   Drug: enzalutamide;   Drug: abiraterone;   Drug: prednisone
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Astellas Pharma US, Inc.;   Medivation, Inc.;   Biologics, Inc.
  Active, not recruiting
• Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

  NCT01901094

  Conditions:   Stage II Breast Cancer;   Stage IIIA Breast Cancer
  Interventions:   Procedure: Axillary Lymph Node Dissection (ALND);   Radiation: Nodal Radiation Therapy;   Radiation: Axillary Radiation Therapy
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

  NCT01841736

  Conditions:   Atypical Carcinoid Tumor;   Foregut Carcinoid Tumor;   Hindgut Carcinoid Tumor;   Metastatic Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Midgut Carcinoid Tumor;   Recurrent Digestive System Neuroendocrine Tumor G1;   Regional Digestive System Neuroendocrine Tumor G1
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Pazopanib;   Drug: Pazopanib Hydrochloride;   Other: Placebo;   Other: Quality-of-Life Assessment
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

  NCT01835158

  Conditions:   Clear Cell Renal Cell Carcinoma;   Metastatic Kidney Carcinoma;   Stage III Renal Cell Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7
  Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Drug: Sunitinib Malate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

  NCT01824875

  Conditions:   Gastrinoma;   Glucagonoma;   Insulinoma;   Islet Cell Carcinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
  Interventions:   Drug: temozolomide;   Drug: capecitabine;   Other: laboratory biomarker analysis
  Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

  NCT02152982

  Conditions:   Glioblastoma;   Gliosarcoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment;   Drug: Temozolomide;   Drug: Veliparib
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma

  NCT01781468

  Condition:   Fatigue
  Interventions:   Drug: armodafinil 150 mg;   Other: Placebo;   Drug: armodafinil 250 mg
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Active, not recruiting
• S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

  NCT01809691

  Condition:   Prostate Cancer
  Interventions:   Drug: TAK-700;   Drug: Bicalutamide
  Sponsors:   Southwest Oncology Group;   Millennium Pharmaceuticals, Inc.;   National Cancer Institute (NCI)
  Active, not recruiting
• Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

  NCT01286272

  Conditions:   Ann Arbor Stage III Grade 1 Follicular Lymphoma;   Ann Arbor Stage III Grade 2 Follicular Lymphoma;   Ann Arbor Stage III Grade 3 Follicular Lymphoma;   Ann Arbor Stage IV Grade 1 Follicular Lymphoma;   Ann Arbor Stage IV Grade 2 Follicular Lymphoma;   Ann Arbor Stage IV Grade 3 Follicular Lymphoma;   Grade 3a Follicular Lymphoma
  Interventions:   Drug: Bendamustine Hydrochloride;   Drug: Bortezomib;   Radiation: Fludeoxyglucose F-18;   Other: Laboratory Biomarker Analysis;   Biological: Ofatumumab;   Procedure: Positron Emission Tomography with Radiolabeled Targeting Agent
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia

  NCT03204916

  Condition:   Acute Lymphoblastic Leukemia
  Interventions:   Other: Medical Chart Review;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

  NCT01674140

  Condition:   Breast Cancer
  Interventions:   Drug: anastrozole;   Drug: everolimus;   Drug: exemestane;   Drug: goserelin acetate;   Drug: letrozole;   Drug: leuprolide acetate;   Drug: tamoxifen citrate;   Other: placebo
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

  NCT01668719

  Conditions:   DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma
  Interventions:   Drug: Bortezomib;   Drug: Dexamethasone;   Biological: Elotuzumab;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer

  NCT01556243

  Condition:   Breast Cancer
  Interventions:   Procedure: therapeutic conventional surgery;   Radiation: whole breast irradiation
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Active, not recruiting
• Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma

  NCT01856192

  Conditions:   Ann Arbor Stage II Diffuse Large B-Cell Lymphoma;   Ann Arbor Stage III Diffuse Large B-Cell Lymphoma;   Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma;   CD20 Positive
  Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery

  NCT01515787

  Condition:   Colorectal Cancer
  Interventions:   Drug: FOLFOX (chemotherapy);   Other: 5 FUCMT (chemoradiation);   Procedure: surgery;   Procedure: magnetic resonance imaging or endorectal ultrasound
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Active, not recruiting
• S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer

  NCT01498289

  Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer;   Gastric Cancer
  Interventions:   Drug: FOLFOX regimen;   Drug: docetaxel;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

  NCT01415752

  Conditions:   Lymphoma;   Neurotoxicity;   Therapy-related Toxicity
  Interventions:   Biological: rituximab;   Drug: bendamustine hydrochloride;   Drug: bortezomib;   Drug: lenalidomide
  Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

  NCT01386385

  Conditions:   Lung Adenocarcinoma;   Lung Adenocarcinoma, Mixed Subtype;   Lung Large Cell Carcinoma;   Lung Squamous Cell Carcinoma;   Minimally Invasive Lung Adenocarcinoma;   Stage III Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIB Lung Non-Small Cell Cancer AJCC v7
  Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Placebo;   Drug: Veliparib
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• S0820, Adenoma and Second Primary Prevention Trial

  NCT01349881

  Condition:   Colorectal Neoplasms
  Interventions:   Drug: Eflornithine placebo & sulindac placebo;   Drug: eflornithine & sulindac placebo;   Drug: Eflornithine placebo & sulindac;   Drug: Eflornithine plus sulindac
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Cancer Prevention Pharmaceuticals, Inc.
  Recruiting
• PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy

  NCT01333033

  Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer
  Interventions:   Drug: Oxaliplatin;   Drug: Leucovorin Calcium;   Drug: Fluorouracil;   Drug: Carboplatin;   Drug: Paclitaxel;   Procedure: Positron Emission Tomography;   Procedure: Computed Tomography;   Radiation: Radiation Therapy
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Active, not recruiting
• Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

  NCT01272037

  Conditions:   Ductal Breast Carcinoma In Situ;   Estrogen Receptor Positive;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Multicentric Breast Carcinoma;   Multifocal Breast Carcinoma;   Progesterone Receptor Positive;   Synchronous Bilateral Breast Carcinoma
  Interventions:   Drug: Anastrozole;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Quality-of-Life Assessment;   Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

  NCT01275677

  Conditions:   Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7
  Interventions:   Drug: Cyclophosphamide;   Drug: Docetaxel;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Biological: Trastuzumab
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance

  NCT01238172

  Condition:   Prostate Cancer
  Interventions:   Other: dietary education and counseling;   Other: prostate cancer foundation booklet
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Completed
• Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

  NCT01229943

  Conditions:   Pancreatic Gastrinoma;   Pancreatic Neuroendocrine Tumor G1;   Pancreatic Neuroendocrine Tumor G2;   Pancreatic Vipoma;   Recurrent Pancreatic Neuroendocrine Carcinoma
  Interventions:   Biological: Bevacizumab;   Drug: Everolimus;   Drug: Octreotide Acetate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy

  NCT01198158

  Conditions:   Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Carcinoma;   Stage III Renal Cell Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7
  Interventions:   Biological: Bevacizumab;   Drug: Everolimus;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Terminated
• Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

  NCT01167712

  Conditions:   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Ovarian Brenner Tumor;   Ovarian Clear Cell Adenocarcinofibroma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Ovarian Undifferentiated Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Stage IIA Fallopian Tube Cancer AJCC v6 and v7;   Stage IIA Ovarian Cancer AJCC V6 and v7;   Stage IIB Fallopian Tube Cancer AJCC v6 and v7;   Stage IIB Ovarian Cancer AJCC v6 and v7;   Stage IIC Fallopian Tube Cancer AJCC v6 and v7;   Stage IIC Ovarian Cancer AJCC v6 and v7;   Stage IIIA Fallopian Tube Cancer AJCC v7;   Stage IIIA Ovarian Cancer AJCC v6 and v7;   Stage IIIA Primary Peritoneal Cancer AJCC v7;   Stage IIIB Fallopian Tube Cancer AJCC v7;   Stage IIIB Ovarian Cancer AJCC v6 and v7;   Stage IIIB Primary Peritoneal Cancer AJCC v7;   Stage IIIC Fallopian Tube Cancer AJCC v7;   Stage IIIC Ovarian Cancer AJCC v6 and v7;   Stage IIIC Primary Peritoneal Cancer AJCC v7;   Stage IV Fallopian Tube Cancer AJCC v6 and v7;   Stage IV Ovarian Cancer AJCC v6 and v7;   Stage IV Primary Peritoneal Cancer AJCC v7
  Interventions:   Biological: Bevacizumab;   Drug: Carboplatin;   Procedure: Computed Tomography;   Drug: Paclitaxel;   Procedure: Therapeutic Conventional Surgery
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

  NCT01120249

  Condition:   Kidney Cancer
  Interventions:   Drug: everolimus;   Other: placebo
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer

  NCT03598257

  Condition:   Inflammatory Breast Carcinoma
  Interventions:   Drug: Olaparib;   Radiation: Radiation Therapy
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy

  NCT01099449

  Conditions:   Chemotherapeutic Agent Toxicity;   Colorectal Cancer;   Neuropathy;   Neurotoxicity
  Interventions:   Drug: calcium gluconate;   Drug: magnesium sulfate;   Other: placebo;   Drug: oxaliplatin
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Completed
• Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

  NCT01015833

  Conditions:   Advanced Adult Hepatocellular Carcinoma;   Recurrent Hepatocellular Carcinoma;   Stage III Hepatocellular Carcinoma AJCC v7;   Stage IIIA Hepatocellular Carcinoma AJCC v7;   Stage IIIB Hepatocellular Carcinoma AJCC v7;   Stage IIIC Hepatocellular Carcinoma AJCC v7;   Stage IV Hepatocellular Carcinoma AJCC v7;   Stage IVA Hepatocellular Carcinoma AJCC v7;   Stage IVB Hepatocellular Carcinoma AJCC v7;   Unresectable Hepatocellular Carcinoma
  Interventions:   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Drug: Sorafenib Tosylate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

  NCT01004978

  Conditions:   Hepatocellular Carcinoma;   Unresectable Hepatocellular Carcinoma
  Interventions:   Drug: Cisplatin;   Drug: Doxorubicin Hydrochloride;   Drug: Doxorubicin-Eluting Beads;   Other: Laboratory Biomarker Analysis;   Drug: Mitomycin;   Other: Pharmacological Study;   Other: Placebo;   Drug: Sorafenib Tosylate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery

  NCT03375320

  Conditions:   Atypical Carcinoid Tumor;   Carcinoid Tumor;   Digestive System Neuroendocrine Neoplasm;   Functioning Pancreatic Neuroendocrine Tumor;   Intermediate Grade Lung Neuroendocrine Neoplasm;   Low Grade Lung Neuroendocrine Neoplasm;   Lung Atypical Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Neuroendocrine Neoplasm;   Non-Functioning Pancreatic Neuroendocrine Tumor;   Pancreatic Neuroendocrine Tumor;   Serotonin-Producing Pancreatic Neuroendocrine Tumor;   Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7;   Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7;   Stage IV Digestive System Neuroendocrine Tumor AJCC v7
  Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

  NCT00977574

  Conditions:   Endometrial Adenocarcinoma;   Endometrial Adenosquamous Carcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage IIIA Uterine Corpus Cancer AJCC v7;   Stage IIIB Uterine Corpus Cancer AJCC v7;   Stage IIIC Uterine Corpus Cancer AJCC v7;   Stage IVA Uterine Corpus Cancer AJCC v7;   Stage IVB Uterine Corpus Cancer AJCC v7
  Interventions:   Biological: Bevacizumab;   Drug: Carboplatin;   Drug: Ixabepilone;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Drug: Temsirolimus
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

  NCT00972478

  Conditions:   Ann Arbor Stage II Non-Hodgkin Lymphoma;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma
  Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate;   Drug: Vorinostat
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

  NCT00951496

  Conditions:   Ovarian Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Carcinoma;   Stage IIA Fallopian Tube Cancer AJCC v6 and v7;   Stage IIA Ovarian Cancer AJCC V6 and v7;   Stage IIB Fallopian Tube Cancer AJCC v6 and v7;   Stage IIB Ovarian Cancer AJCC v6 and v7;   Stage IIC Fallopian Tube Cancer AJCC v6 and v7;   Stage IIC Ovarian Cancer AJCC v6 and v7;   Stage IIIA Fallopian Tube Cancer AJCC v7;   Stage IIIA Ovarian Cancer AJCC v6 and v7;   Stage IIIA Primary Peritoneal Cancer AJCC v7;   Stage IIIB Fallopian Tube Cancer AJCC v7;   Stage IIIB Ovarian Cancer AJCC v6 and v7;   Stage IIIB Primary Peritoneal Cancer AJCC v7;   Stage IIIC Fallopian Tube Cancer AJCC v7;   Stage IIIC Ovarian Cancer AJCC v6 and v7;   Stage IIIC Primary Peritoneal Cancer AJCC v7
  Interventions:   Biological: Bevacizumab;   Drug: Carboplatin;   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

  NCT00946712

  Conditions:   Recurrent Large Cell Lung Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Large Cell Lung Carcinoma;   Stage IV Lung Adenocarcinoma;   Stage IV Squamous Cell Lung Carcinoma
  Interventions:   Biological: Bevacizumab;   Drug: Carboplatin;   Biological: Cetuximab;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer

  NCT00942357

  Conditions:   Endometrial Clear Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Stage IA Uterine Corpus Cancer AJCC v7;   Stage IB Uterine Corpus Cancer AJCC v7;   Stage II Uterine Corpus Cancer AJCC v7;   Stage IIIA Uterine Corpus Cancer AJCC v7;   Stage IIIB Uterine Corpus Cancer AJCC v7;   Stage IIIC Uterine Corpus Cancer AJCC v7;   Stage IVA Uterine Corpus Cancer AJCC v7
  Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Radiation: Internal Radiation Therapy;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy
  Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

  NCT00942331

  Conditions:   Advanced Urothelial Carcinoma;   Metastatic Bladder Urothelial Carcinoma;   Metastatic Prostate Carcinoma;   Metastatic Renal Pelvis Urothelial Carcinoma;   Metastatic Ureter Urothelial Carcinoma;   Metastatic Urethral Urothelial Carcinoma;   Metastatic Urothelial Carcinoma;   Stage IV Bladder Urothelial Carcinoma AJCC v7;   Stage IV Prostate Cancer AJCC v7;   Stage IV Renal Pelvis Cancer AJCC v7;   Stage IV Ureter Cancer AJCC v7;   Stage IV Urethral Cancer AJCC v7;   Unresectable Urothelial Carcinoma
  Interventions:   Biological: Bevacizumab;   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

  NCT00731731

  Conditions:   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Cognitive Side Effects of Cancer Therapy
  Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Procedure: Cognitive Assessment;   Other: Laboratory Biomarker Analysis;   Drug: Temozolomide;   Drug: Vorinostat
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva

  NCT01595061

  Conditions:   Stage IIIA Vulvar Cancer AJCC v7;   Stage IIIB Vulvar Cancer AJCC v7;   Stage IIIC Vulvar Cancer AJCC v7;   Stage IVA Vulvar Cancer AJCC v7;   Vulvar Squamous Cell Carcinoma
  Interventions:   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Radiation: Intensity-Modulated Radiation Therapy;   Procedure: Therapeutic Conventional Surgery
  Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

  NCT00807768

  Conditions:   Endometrial Clear Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Fatigue;   Neurotoxicity Syndrome;   Obesity;   Stage I Uterine Corpus Cancer AJCC v7;   Stage II Uterine Corpus Cancer AJCC v7
  Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Carboplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Internal Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

  NCT00803062

  Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma;   Recurrent Cervical Carcinoma;   Stage IVB Cervical Cancer
  Interventions:   Biological: Bevacizumab;   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Topotecan Hydrochloride
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Completed
• Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

  NCT01522976

  Conditions:   Chronic Myelomonocytic Leukemia;   Chronic Myelomonocytic Leukemia-1;   Chronic Myelomonocytic Leukemia-2;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts;   Myelodysplastic Syndrome With Excess Blasts-1;   Myelodysplastic Syndrome With Excess Blasts-2;   Previously Treated Myelodysplastic Syndrome
  Interventions:   Drug: Azacitidine;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Drug: Vorinostat
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

  NCT00785291

  Conditions:   Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Negative;   HER2/Neu Positive;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIC Breast Cancer AJCC v6;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Biological: Bevacizumab;   Drug: Ixabepilone;   Other: Laboratory Biomarker Analysis;   Drug: Nab-paclitaxel;   Drug: Paclitaxel;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

  NCT00769379

  Conditions:   Ductal Breast Carcinoma In Situ;   HER2/Neu Positive
  Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Trastuzumab;   Radiation: Whole Breast Irradiation
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

  NCT01013649

  Conditions:   Pancreatic Acinar Cell Carcinoma;   Pancreatic Ductal Adenocarcinoma;   Pancreatic Intraductal Papillary-Mucinous Neoplasm;   Stage I Pancreatic Cancer AJCC v6 and v7;   Stage IA Pancreatic Cancer AJCC v6 and v7;   Stage IB Pancreatic Cancer AJCC v6 and v7;   Stage II Pancreatic Cancer AJCC v6 and v7;   Stage IIA Pancreatic Cancer AJCC v6 and v7;   Stage IIB Pancreatic Cancer AJCC v6 and v7
  Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Capecitabine;   Drug: Chemotherapy;   Drug: Erlotinib Hydrochloride;   Drug: Fluorouracil;   Drug: Gemcitabine Hydrochloride;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

  NCT00644228

  Conditions:   DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma
  Interventions:   Drug: Bortezomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer

  NCT00601900

  Conditions:   Estrogen Receptor Positive;   Invasive Breast Carcinoma;   Postmenopausal;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage III Breast Cancer AJCC v6;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Questionnaire Administration;   Drug: Tamoxifen Citrate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms

  NCT00443274

  Condition:   Breast Implant
  Interventions:   Other: NBIR Placeholder;   Device: 410 Arm;   Device: BIFs
  Sponsor:   Allergan
  Recruiting
• ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

  NCT00490139

  Condition:   Neoplasms, Breast
  Interventions:   Drug: Lapatinib;   Biological: Trastuzumab
  Sponsors:   Novartis Pharmaceuticals;   North Central Cancer Treatment Group;   National Cancer Institute (NCI);   Breast International Group;   Canadian Cancer Trials Group
  Active, not recruiting
• Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery

  NCT00326898

  Conditions:   Clear Cell Renal Cell Carcinoma;   Stage I Renal Cell Cancer AJCC v6 and v7;   Stage II Renal Cell Cancer AJCC v7;   Stage III Renal Cell Cancer AJCC v7
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment;   Drug: Sorafenib Tosylate;   Drug: Sunitinib Malate
  Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   Southwest Oncology Group
  Completed
• Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

  NCT00324805

  Conditions:   Stage IB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7
  Interventions:   Biological: Bevacizumab;   Drug: Cisplatin;   Drug: Docetaxel;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Pemetrexed Disodium;   Other: Questionnaire Administration;   Drug: Vinorelbine Tartrate
  Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group;   Southwest Oncology Group
  Active, not recruiting
• Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

  NCT00310180

  Conditions:   Breast Adenocarcinoma;   Estrogen Receptor and/or Progesterone Receptor Positive;   HER2/Neu Negative;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage IIIB Breast Cancer AJCC v7
  Interventions:   Drug: Anastrozole;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Drug: Tamoxifen Citrate
  Sponsors:   National Cancer Institute (NCI);   American College of Surgeons;   Cancer and Leukemia Group B;   NSABP Foundation Inc;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group;   Southwest Oncology Group
  Active, not recruiting
• Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

  NCT00262847

  Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
  Interventions:   Biological: Bevacizumab;   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Placebo;   Other: Quality-of-Life Assessment
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Completed
• Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer

  NCT00262821

  Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Cervical Cancer;   Stage IVA Cervical Cancer
  Interventions:   Drug: cisplatin;   Drug: tirapazamine
  Sponsors:   National Cancer Institute (NCI);   NCIC Clinical Trials Group;   Gynecologic Oncology Group
  Terminated
• Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

  NCT00217737

  Conditions:   Colon Mucinous Adenocarcinoma;   Colon Signet Ring Cell Adenocarcinoma;   Lynch Syndrome;   Stage IIA Colon Cancer AJCC v7;   Stage IIB Colon Cancer AJCC v7;   Stage IIC Colon Cancer AJCC v7
  Interventions:   Biological: Bevacizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting

  NCT01808573

  Condition:   HER2+ Metastatic Breast Cancer (MBC)
  Interventions:   Drug: neratinib;   Drug: capecitabine;   Drug: lapatinib
  Sponsor:   Puma Biotechnology, Inc.
  Active, not recruiting
• Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer

  NCT01672892

  Conditions:   Cervical Cancer;   Endometrial Cancer;   Gastrointestinal Complications;   Perioperative/Postoperative Complications;   Radiation Toxicity;   Urinary Complications;   Urinary Tract Toxicity
  Interventions:   Radiation: Standard radiation therapy;   Radiation: intensity-modulated radiation therapy
  Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

  NCT00063999

  Conditions:   Recurrent Uterine Corpus Carcinoma;   Stage IIIA Uterine Corpus Cancer AJCC v7;   Stage IIIB Uterine Corpus Cancer AJCC v7;   Stage IIIC Uterine Corpus Cancer AJCC v7;   Stage IVA Uterine Corpus Cancer AJCC v7;   Stage IVB Uterine Corpus Cancer AJCC v7
  Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Doxorubicin Hydrochloride;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Biological: Pegfilgrastim;   Other: Quality-of-Life Assessment
  Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

  NCT01231906

  Conditions:   Non-Metastatic Extraskeletal Ewing Sarcoma;   Peripheral Primitive Neuroectodermal Tumor of Bone;   Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
  Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Topotecan Hydrochloride;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

  NCT03274687

  Conditions:   Prostate Adenocarcinoma;   Stage I Prostate Adenocarcinoma;   Stage II Prostate Adenocarcinoma;   Stage III Prostate Adenocarcinoma
  Interventions:   Radiation: Hypofractionated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Active, not recruiting
• Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

  NCT03258554

  Conditions:   Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Head and Neck Squamous Cell Carcinoma;   Hypopharyngeal Squamous Cell Carcinoma;   Laryngeal Squamous Cell Carcinoma;   Oral Cavity Squamous Cell Carcinoma;   Oropharyngeal Squamous Cell Carcinoma;   Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Squamous Cell Carcinoma of Unknown Primary;   Stage III Hypopharyngeal Carcinoma AJCC v8;   Stage III Laryngeal Cancer AJCC v8;   Stage III Lip and Oral Cavity Cancer AJCC v8;   Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8;   Stage IVA Hypopharyngeal Carcinoma AJCC v8;   Stage IVA Laryngeal Cancer AJCC v8;   Stage IVA Lip and Oral Cavity Cancer AJCC v8;   Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8;   Stage IVB Hypopharyngeal Carcinoma AJCC v8;   Stage IVB Laryngeal Cancer AJCC v8;   Stage IVB Lip and Oral Cavity Cancer AJCC v8;   Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
  Interventions:   Biological: Cetuximab;   Biological: Durvalumab;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group;   NRG Oncology
  Recruiting
• Paclitaxel, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Patients With Metastatic Breast Cancer

  NCT03199885

  Conditions:   Breast Adenocarcinoma;   HER2/Neu Positive;   Metastatic Breast Carcinoma;   Recurrent Breast Carcinoma;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Drug: Atezolizumab;   Drug: Paclitaxel;   Biological: Pertuzumab;   Other: Placebo;   Other: Quality-of-Life Assessment;   Biological: Trastuzumab
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• S1417CD Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer

  NCT02728804

  Conditions:   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
  Interventions:   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Treating Patients With Limited Stage or Extensive Stage Small Cell Lung Cancer

  NCT02635009

  Conditions:   Extensive Stage Small Cell Lung Carcinoma;   Limited Stage Small Cell Lung Carcinoma
  Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Other: Cognitive Assessment;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
  Recruiting
• Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer

  NCT02186847

  Conditions:   Adenosquamous Lung Carcinoma;   Bronchioloalveolar Carcinoma;   Large Cell Lung Carcinoma;   Lung Adenocarcinoma;   Non-Small Cell Lung Carcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Squamous Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer
  Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Carboplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: Metformin Hydrochloride;   Drug: Paclitaxel;   Radiation: Volume Modulated Arc Therapy
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Active, not recruiting
• Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

  NCT02135042

  Conditions:   Epstein-Barr Virus Infection;   Stage II Nasopharyngeal Carcinoma;   Stage III Nasopharyngeal Carcinoma;   Stage IVA Nasopharyngeal Carcinoma;   Stage IVB Nasopharyngeal Carcinoma
  Interventions:   Drug: Cisplatin;   Other: Clinical Observation;   Drug: Fluorouracil;   Drug: Gemcitabine Hydrochloride;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

  NCT02032823

  Condition:   Breast Cancer
  Interventions:   Drug: Olaparib;   Drug: Placebo
  Sponsors:   AstraZeneca;   Breast International Group;   Frontier Science & Technology Research Foundation, Inc.;   NRG Oncology;   Myriad Genetic Laboratories, Inc.;   Br.E.A.S.T. -Data Center & Operational Office Institut Jules Bordet;   Merck Sharp & Dohme Corp.
  Active, not recruiting
• Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

  NCT03067181

  Conditions:   Adult Germ Cell Tumor;   Childhood Extracranial Germ Cell Tumor;   Childhood Germ Cell Tumor;   Extragonadal Embryonal Carcinoma;   Grade 2 Ovarian Teratoma;   Malignant Germ Cell Tumor;   Malignant Ovarian Teratoma;   Stage I Ovarian Choriocarcinoma;   Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage I Ovarian Teratoma AJCC v6 and v7;   Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage I Testicular Choriocarcinoma AJCC v6 and v7;   Stage I Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage I Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage II Ovarian Choriocarcinoma;   Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage II Testicular Choriocarcinoma AJCC v6 and v7;   Stage II Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage II Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage III Ovarian Choriocarcinoma;   Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage III Testicular Choriocarcinoma AJCC v6 and v7;   Stage III Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage III Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage IV Ovarian Choriocarcinoma;   Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7;   Testicular Mixed Choriocarcinoma and Embryonal Carcinoma;   Testicular Mixed Choriocarcinoma and Teratoma;   Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
  Interventions:   Other: Best Practice;   Drug: Bleomycin;   Biological: Bleomycin Sulfate;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

  NCT02883049

  Conditions:   B Acute Lymphoblastic Leukemia;   Central Nervous System Leukemia;   Ph-Like Acute Lymphoblastic Leukemia;   Testicular Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
  Interventions:   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

  NCT02867592

  Conditions:   Adrenal Cortex Carcinoma;   Alveolar Soft Part Sarcoma;   Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Clear Cell Sarcoma of Soft Tissue;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   MITF Positive;   Osteosarcoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Osteosarcoma;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma;   Recurrent Thyroid Gland Medullary Carcinoma;   Refractory Ewing Sarcoma;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Refractory Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma;   Renal Cell Carcinoma;   Rhabdomyosarcoma;   Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma;   Solid Neoplasm;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
  Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

  NCT01368588

  Condition:   Prostate Cancer
  Interventions:   Radiation: radiation therapy;   Radiation: Whole-pelvic radiotherapy (WPRT)
  Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

  NCT02567435

  Conditions:   Alveolar Rhabdomyosarcoma;   Botryoid-Type Embryonal Rhabdomyosarcoma;   Embryonal Rhabdomyosarcoma;   Rhabdomyosarcoma;   Sclerosing Rhabdomyosarcoma;   Spindle Cell Rhabdomyosarcoma;   Untreated Childhood Rhabdomyosarcoma
  Interventions:   Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Temsirolimus;   Drug: Vincristine Sulfate;   Drug: Vinorelbine
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

  NCT02306161

  Conditions:   Metastatic Ewing Sarcoma;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Bone Marrow;   Metastatic Malignant Neoplasm in the Lung;   Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone;   Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
  Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Radiation: External Beam Radiation Therapy;   Biological: Ganitumab;   Drug: Ifosfamide;   Radiation: Stereotactic Radiosurgery;   Procedure: Therapeutic Surgical Procedure;   Drug: Vincristine;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

  NCT01081262

  Conditions:   Borderline Ovarian Mucinous Tumor;   Ovarian Mucinous Cystadenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Stage IA Fallopian Tube Cancer AJCC v6 and v7;   Stage IA Ovarian Cancer AJCC v6 and v7;   Stage IB Fallopian Tube Cancer AJCC v6 and v7;   Stage IB Ovarian Cancer AJCC v6 and v7;   Stage IC Fallopian Tube Cancer AJCC v6 and v7;   Stage IC Ovarian Cancer AJCC v6 and v7;   Stage IIA Fallopian Tube Cancer AJCC v6 and v7;   Stage IIA Ovarian Cancer AJCC V6 and v7;   Stage IIB Fallopian Tube Cancer AJCC v6 and v7;   Stage IIB Ovarian Cancer AJCC v6 and v7;   Stage IIC Fallopian Tube Cancer AJCC v6 and v7;   Stage IIC Ovarian Cancer AJCC v6 and v7;   Stage IIIA Fallopian Tube Cancer AJCC v7;   Stage IIIA Ovarian Cancer AJCC v6 and v7;   Stage IIIB Fallopian Tube Cancer AJCC v7;   Stage IIIB Ovarian Cancer AJCC v6 and v7;   Stage IIIC Fallopian Tube Cancer AJCC v7;   Stage IIIC Ovarian Cancer AJCC v6 and v7;   Stage IV Fallopian Tube Cancer AJCC v6 and v7;   Stage IV Ovarian Cancer AJCC v6 and v7
  Interventions:   Biological: Bevacizumab;   Drug: Capecitabine;   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Oxaliplatin;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma

  NCT01062425

  Conditions:   Adult Glioblastoma;   Adult Gliosarcoma
  Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Cediranib Maleate;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Drug: Temozolomide
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology;   Radiation Therapy Oncology Group
  Active, not recruiting
• Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

  NCT00958698

  Conditions:   Fallopian Tube Carcinoma;   Primary Peritoneal Carcinoma;   Psychological Impact of Cancer;   Recurrent Ovarian Carcinoma
  Interventions:   Other: Communication Intervention;   Other: Educational Intervention;   Other: Internet-Based Intervention;   Procedure: Psychosocial Assessment and Care;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer

  NCT00655876

  Condition:   Esophageal Cancer
  Interventions:   Drug: cetuximab;   Drug: cisplatin;   Drug: paclitaxel;   Radiation: radiation therapy
  Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)

  NCT00373685

  Condition:   Osteoarthritis
  Interventions:   Drug: Celecoxib;   Drug: Any commercially available NSAID with the indication for osteoarthritis
  Sponsor:   Pfizer
  Completed
• Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

  NCT01190930

  Conditions:   Acute Lymphoblastic Leukemia;   Adult B Lymphoblastic Lymphoma;   Ann Arbor Stage I B Lymphoblastic Lymphoma;   Ann Arbor Stage II B Lymphoblastic Lymphoma;   Childhood B Acute Lymphoblastic Leukemia;   Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Childhood B Lymphoblastic Lymphoma;   Down Syndrome;   Hypodiploid B Acute Lymphoblastic Leukemia;   Intrachromosomal Amplification of Chromosome 21;   Philadelphia Chromosome Positive;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
  Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Thioguanine;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

  NCT00980460

  Conditions:   Alpha Fetoprotein Increased;   PRETEXT Stage 1 Hepatoblastoma;   PRETEXT Stage 2 Hepatoblastoma;   PRETEXT Stage 3 Hepatoblastoma;   PRETEXT Stage 4 Hepatoblastoma
  Interventions:   Drug: Cisplatin;   Drug: Dexrazoxane;   Drug: Doxorubicin Hydrochloride;   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Procedure: Liver Transplantation;   Drug: Temsirolimus;   Procedure: Therapeutic Conventional Surgery;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

  NCT00904241

  Conditions:   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4 Neuroblastoma;   Stage 4S Neuroblastoma
  Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Study of Kidney Tumors in Younger Patients

  NCT00898365

  Conditions:   Adult Cystic Nephroma;   Anaplastic Kidney Wilms Tumor;   Angiolipoma;   Cellular Congenital Mesoblastic Nephroma;   Classic Congenital Mesoblastic Nephroma;   Clear Cell Sarcoma of the Kidney;   Congenital Mesoblastic Nephroma;   Cystic Partially Differentiated Kidney Nephroblastoma;   Diffuse Hyperplastic Perilobar Nephroblastomatosis;   Extrarenal Rhabdoid Tumor;   Kidney Medullary Carcinoma;   Kidney Neoplasm;   Kidney Oncocytoma;   Kidney Wilms Tumor;   Metanephric Adenofibroma;   Metanephric Adenoma;   Metanephric Stromal Tumor;   Metanephric Tumor;   Mixed Congenital Mesoblastic Nephroma;   Ossifying Renal Tumor of Infancy;   Papillary Renal Cell Carcinoma;   Renal Cell Carcinoma;   Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions;   Rhabdoid Tumor of the Kidney;   Wilms Tumor
  Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Suspended
• Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

  NCT00408005

  Conditions:   T Acute Lymphoblastic Leukemia;   T Lymphoblastic Lymphoma
  Interventions:   Drug: Asparaginase;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Nelarabine;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Completed
• A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

  NCT03495102

  Condition:   Diabetes Mellitus, Type 2
  Intervention:   Drug: Dulaglutide
  Sponsor:   Eli Lilly and Company
  Active, not recruiting
• Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

  NCT03248882

  Conditions:   Nonalcoholic Fatty Liver Disease;   Nonalcoholic Steatohepatitis
  Interventions:   Drug: Placebo;   Drug: PF-05221304
  Sponsor:   Pfizer
  Completed
• DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer [DESTINY-Breast01]

  NCT03248492

  Condition:   Breast Cancer
  Intervention:   Drug: DS-8201a
  Sponsors:   Daiichi Sankyo, Inc.;   Daiichi Sankyo Co., Ltd.;   AstraZeneca
  Active, not recruiting
• Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

  NCT03180268

  Conditions:   Grade II Meningioma;   Intracranial Meningioma
  Interventions:   Other: Clinical Observation;   Radiation: Radiation Therapy
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

  NCT03137771

  Conditions:   Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer
  Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy (3D-CRT);   Drug: Docetaxel;   Drug: Gemcitabine;   Radiation: Intensity-Modulated Radiation Therapy (IMRT);   Drug: Pemetrexed Disodium;   Radiation: Stereotactic Body Radiation Therapy (SBRT);   Drug: Erlotinib Hydrochloride;   Drug: Pembrolizumab
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

  NCT03022825

  Condition:   Bladder Cancer
  Interventions:   Drug: ALT-803;   Drug: BCG
  Sponsor:   Altor BioScience
  Recruiting
• A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

  NCT03009981

  Condition:   Prostate Cancer
  Interventions:   Drug: Apalutamide;   Drug: LHRH Analogue;   Drug: Abiraterone Acetate;   Drug: Prednisone
  Sponsors:   Alliance Foundation Trials, LLC.;   Janssen Research & Development, LLC
  Recruiting
• S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)

  NCT02728596

  Conditions:   Febrile Neutropenia;   Stage 0 Breast Cancer;   Stage 0 Colorectal Cancer;   Stage 0 Non-Small Cell Lung Cancer;   Stage I Colorectal Cancer;   Stage IA Breast Cancer;   Stage IA Non-Small Cell Lung Carcinoma;   Stage IB Breast Cancer;   Stage IB Non-Small Cell Lung Carcinoma;   Stage IIA Breast Cancer;   Stage IIA Colorectal Cancer;   Stage IIA Non-Small Cell Lung Carcinoma;   Stage IIB Breast Cancer;   Stage IIB Colorectal Cancer;   Stage IIB Non-Small Cell Lung Carcinoma;   Stage IIC Colorectal Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Colorectal Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Colorectal Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colorectal Cancer;   Stage IV Breast Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IVA Colorectal Cancer;   Stage IVB Colorectal Cancer
  Interventions:   Other: Preventive Intervention;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Patient-Centered Outcomes Research Institute
  Recruiting
• Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction

  NCT02929329

  Condition:   Heart Failure
  Interventions:   Drug: Omecamtiv Mecarbil;   Drug: Placebo
  Sponsors:   Amgen;   Cytokinetics;   Servier
  Active, not recruiting
• Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT02502266

  Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Ovarian Undifferentiated Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
  Interventions:   Drug: Cediranib;   Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Questionnaire Administration;   Drug: Topotecan;   Drug: Topotecan Hydrochloride
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT02470585

  Conditions:   Ovarian Cancer;   Ovarian Neoplasm
  Interventions:   Drug: Veliparib;   Drug: Paclitaxel;   Drug: Carboplatin;   Other: Placebo
  Sponsors:   AbbVie;   Gynecologic Oncology Group;   Australia New Zealand Gynaecological Oncology Group
  Active, not recruiting
• Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT02446600

  Conditions:   BRCA Rearrangement;   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Tumor;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Tumor;   Ovarian Transitional Cell Carcinoma;   Ovarian Undifferentiated Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Ovarian Endometrioid Adenocarcinoma;   Recurrent Primary Peritoneal Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Cediranib Maleate;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment
  Sponsors:   National Cancer Institute (NCI);   AstraZeneca;   NRG Oncology
  Active, not recruiting
• Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer

  NCT02254278

  Conditions:   Stage III Oropharyngeal Squamous Cell Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma;   Stage IVC Oropharyngeal Squamous Cell Carcinoma;   Tongue Carcinoma
  Interventions:   Drug: Cisplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Active, not recruiting
• Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

  NCT01844986

  Conditions:   Newly Diagnosed;   Advanced Ovarian Cancer;   FIGO Stage III-IV;   BRCA Mutation;   Complete Response;   Partial Response;   First Line Platinum Chemotherapy
  Intervention:   Drug: Olaparib 300mg tablets
  Sponsors:   AstraZeneca;   Gynecologic Oncology Group (GOG);   Myriad Genetic Laboratories, Inc.;   Merck Sharp & Dohme Corp.
  Active, not recruiting
• Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

  NCT01822496

  Conditions:   Stage III Non-Small Cell Lung Cancer AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7;   Stage IIIB Non-Small Cell Lung Cancer AJCC v7
  Interventions:   Radiation: Radiation Therapy;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Erlotinib;   Drug: Etoposide;   Drug: Paclitaxel
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Terminated
• Project: Every Child for Younger Patients With Cancer

  NCT02402244

  Conditions:   Central Nervous System Neoplasm;   Childhood Immature Teratoma;   Childhood Langerhans Cell Histiocytosis;   Childhood Malignant Neoplasm;   Childhood Mature Teratoma;   Congenital Mesoblastic Nephroma;   Desmoid-Type Fibromatosis;   Lymphoproliferative Disorder;   Myeloproliferative Neoplasm;   Stromal Neoplasm
  Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Medical Chart Review
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery

  NCT01101451

  Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Stage I Cervical Cancer AJCC v6 and v7;   Stage IA Cervical Cancer AJCC v6 and v7;   Stage IB Cervical Cancer AJCC v6 and v7;   Stage IIA Cervical Cancer AJCC v7
  Interventions:   Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer

  NCT01101438

  Condition:   Breast Cancer
  Interventions:   Drug: metformin hydrochloride;   Other: placebo
  Sponsors:   Canadian Cancer Trials Group;   National Cancer Institute (NCI);   International Breast Cancer Study Group;   ICR-CTSU
  Active, not recruiting
• Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

  NCT00980954

  Condition:   Cervical Cancer
  Interventions:   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel
  Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

  NCT01979536

  Conditions:   Anaplastic Large Cell Lymphoma, ALK-Positive;   Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma;   Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma;   Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma;   CD30-Positive Neoplastic Cells Present
  Interventions:   Drug: Brentuximab Vedotin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Ifosfamide;   Drug: Methotrexate
  Sponsor:   National Cancer Institute (NCI)
  Suspended
• Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas

  NCT01793233

  Conditions:   Acute Lymphoblastic Leukemia;   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-Cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-Cell Lymphoma;   Ann Arbor Stage I Adult Burkitt Lymphoma;   Ann Arbor Stage I Adult Hodgkin Lymphoma;   Ann Arbor Stage I Adult Immunoblastic Lymphoma;   Ann Arbor Stage I Adult Lymphoblastic Lymphoma;   Ann Arbor Stage I Adult T-Cell Leukemia/Lymphoma;   Ann Arbor Stage I Childhood Burkitt Lymphoma;   Ann Arbor Stage I Childhood Hodgkin Lymphoma;   Ann Arbor Stage I Childhood Lymphoblastic Lymphoma;   Ann Arbor Stage I Grade 1 Follicular Lymphoma;   Ann Arbor Stage I Grade 2 Follicular Lymphoma;   Ann Arbor Stage I Grade 3 Follicular Lymphoma;   Ann Arbor Stage I Mantle Cell Lymphoma;   Ann Arbor Stage I Marginal Zone Lymphoma;   Ann Arbor Stage I Non-Hodgkin Lymphoma;   Ann Arbor Stage I Noncutaneous Childhood Anaplastic Large Cell Lymphoma;   Ann Arbor Stage I Small Lymphocytic Lymphoma;   Ann Arbor Stage II Adult Contiguous Immunoblastic Lymphoma;   Ann Arbor Stage II Adult Hodgkin Lymphoma;   Ann Arbor Stage II Adult Non-Contiguous Immunoblastic Lymphoma;   Ann Arbor Stage II Adult T-Cell Leukemia/Lymphoma;   Ann Arbor Stage II Childhood Burkitt Lymphoma;   Ann Arbor Stage II Childhood Hodgkin Lymphoma;   Ann Arbor Stage II Childhood Lymphoblastic Lymphoma;   Ann Arbor Stage II Contiguous Adult Burkitt Lymphoma;   Ann Arbor Stage II Contiguous Adult Lymphoblastic Lymphoma;   Ann Arbor Stage II Contiguous Mantle Cell Lymphoma;   Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma;   Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma;   Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma;   Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma;   Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma;   Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma;   Ann Arbor Stage II Marginal Zone Lymphoma;   Ann Arbor Stage II Non-Contiguous Adult Burkitt Lymphoma;   Ann Arbor Stage II Non-Contiguous Adult Lymphoblastic Lymphoma;   Ann Arbor Stage II Non-Contiguous Mantle Cell Lymphoma;   Ann Arbor Stage II Non-Hodgkin Lymphoma;   Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma;   Ann Arbor Stage II Small Lymphocytic Lymphoma;   Ann Arbor Stage III Adult Burkitt Lymphoma;   Ann Arbor Stage III Adult Hodgkin Lymphoma;   Ann Arbor Stage III Adult Immunoblastic Lymphoma;   Ann Arbor Stage III Adult Lymphoblastic Lymphoma;   Ann Arbor Stage III Adult T-Cell Leukemia/Lymphoma;   Ann Arbor Stage III Childhood Burkitt Lymphoma;   Ann Arbor Stage III Childhood Hodgkin Lymphoma;   Ann Arbor Stage III Childhood Lymphoblastic Lymphoma;   Ann Arbor Stage III Grade 1 Follicular Lymphoma;   Ann Arbor Stage III Grade 2 Follicular Lymphoma;   Ann Arbor Stage III Grade 3 Follicular Lymphoma;   Ann Arbor Stage III Mantle Cell Lymphoma;   Ann Arbor Stage III Marginal Zone Lymphoma;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma;   Ann Arbor Stage III Small Lymphocytic Lymphoma;   Ann Arbor Stage IV Adult Burkitt Lymphoma;   Ann Arbor Stage IV Adult Hodgkin Lymphoma;   Ann Arbor Stage IV Adult Immunoblastic Lymphoma;   Ann Arbor Stage IV Adult Lymphoblastic Lymphoma;   Ann Arbor Stage IV Adult T-Cell Leukemia/Lymphoma;   Ann Arbor Stage IV Childhood Burkitt Lymphoma;   Ann Arbor Stage IV Childhood Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma;   Ann Arbor Stage IV Grade 1 Follicular Lymphoma;   Ann Arbor Stage IV Grade 2 Follicular Lymphoma;   Ann Arbor Stage IV Grade 3 Follicular Lymphoma;   Ann Arbor Stage IV Mantle Cell Lymphoma;   Ann Arbor Stage IV Marginal Zone Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma;   Ann Arbor Stage IV Small Lymphocytic Lymphoma;   Childhood Burkitt Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Lymphoma;   Childhood Nasal Type Extranodal NK/T-Cell Lymphoma;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Hairy Cell Leukemia;   Hepatosplenic T-Cell Lymphoma;   Intraocular Lymphoma;   Lymphomatous Involvement of Non-Cutaneous Extranodal Site;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Nodal Marginal Zone Lymphoma;   Non-Hodgkin Lymphoma;   Primary Cutaneous B-Cell Non-Hodgkin Lymphoma;   Progressive Hairy Cell Leukemia Initial Treatment;   Small Intestinal Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage I Mycosis Fungoides and Sezary Syndrome AJCC v7;   Stage IA Mycosis Fungoides and Sezary Syndrome AJCC v7;   Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7;   Stage II Chronic Lymphocytic Leukemia;   Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7;   Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7;   Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7;   Stage III Chronic Lymphocytic Leukemia;   Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7;   Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7;   Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7;   Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7;   Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7;   T-Cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Hairy Cell Leukemia;   Waldenstrom Macroglobulinemia
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors

  NCT01602666

  Conditions:   Central Nervous System Nongerminomatous Germ Cell Tumor;   Childhood Central Nervous System Germinoma
  Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Radiation: Intensity-Modulated Radiation Therapy
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission

  NCT01503632

  Condition:   Childhood Acute Lymphoblastic Leukemia in Remission
  Interventions:   Behavioral: Behavioral Intervention;   Behavioral: Compliance Monitoring;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Other: Questionnaire Administration;   Procedure: Standard Follow-Up Care
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant

  NCT01503515

  Conditions:   Fungal Infection;   Hematopoietic and Lymphoid Cell Neoplasm
  Interventions:   Drug: Caspofungin Acetate;   Drug: Fluconazole;   Other: Laboratory Biomarker Analysis;   Drug: Voriconazole
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

  NCT01371981

  Conditions:   Acute Myeloid Leukemia;   Leukemia Cutis;   Myeloid Neoplasm;   Myeloid Sarcoma;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Myeloid Neoplasm
  Interventions:   Drug: Asparaginase;   Drug: Bortezomib;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Sorafenib Tosylate
  Sponsor:   National Cancer Institute (NCI)
  Completed
• Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma

  NCT01189266

  Conditions:   Anaplastic Astrocytoma;   Anaplastic Oligoastrocytoma;   Brain Stem Glioma;   Childhood Glioblastoma;   Giant Cell Glioblastoma;   Gliosarcoma;   Untreated Childhood Anaplastic Astrocytoma;   Untreated Childhood Anaplastic Oligoastrocytoma;   Untreated Childhood Brain Stem Glioma;   Untreated Childhood Giant Cell Glioblastoma;   Untreated Childhood Gliosarcoma
  Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: Vorinostat
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

  NCT00066690

  Conditions:   Estrogen Receptor Positive Breast Cancer;   Progesterone Receptor Positive Tumor;   Recurrent Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer
  Interventions:   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Procedure: Oophorectomy;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Drug: Tamoxifen;   Drug: Triptorelin
  Sponsors:   International Breast Cancer Study Group;   Breast International Group;   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   NSABP Foundation Inc;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group;   Southwest Oncology Group
  Active, not recruiting
• Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma

  NCT00392327

  Conditions:   Anaplastic Medulloblastoma;   Medulloblastoma;   Untreated Childhood Medulloblastoma
  Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

  NCT00082745

  Conditions:   Cancer Survivor;   Cardiovascular Complication;   Childhood Malignant Neoplasm
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults

  NCT03828617

  Condition:   Pneumococcal Disease
  Interventions:   Biological: 20vPnC;   Biological: 13vPnC
  Sponsor:   Pfizer
  Active, not recruiting
• Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1)

  NCT03740737

  Condition:   Infertility
  Interventions:   Drug: Follitropin delta;   Other: Placebo
  Sponsor:   Ferring Pharmaceuticals
  Active, not recruiting
• Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2)

  NCT03738618

  Condition:   Infertility, Female
  Interventions:   Drug: Follitropin delta;   Drug: Placebo
  Sponsor:   Ferring Pharmaceuticals
  Active, not recruiting
• Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

  NCT03313037

  Condition:   Pneumococcal Infections
  Interventions:   Biological: Multivalent;   Biological: Prevnar 13;   Biological: PPSV23;   Other: Saline
  Sponsor:   Pfizer
  Completed